Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Stock Chart & Stats
$21.85
-$0.42(-4.39%)
At close: 4:00 PM EST
$21.85
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$1.92 - $31.18
Previous CloseN/A
Volume87.32K
Average Volume (3M)660.44K
Market Cap
$1.36B
Enterprise Value$1.15B
Total Cash (Recent Filing)$72.04M
Total Debt (Recent Filing)$62.20M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Mar 26, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,048,428
10 Day Avg. Volume631,820
30 Day Avg. Volume660,436
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.48
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.29
Enterprise Value/Ebitda-6.01
Forecast
1Y Price Target
$41.75Price Target Upside91.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
KSI-101 Efficacy And DurabilityFinal trial data for KSI-101 showed meaningful and sustained vision gains and retinal drying after single dosing, suggesting durable efficacy that could differentiate the candidate in the retinal therapy landscape.
Multi‑indication Commercial OpportunityTarcocimab's potential activity across diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration could create multiple separate revenue streams that add up to significant market potential.
Pivotal Clinical ReadoutsSupportive pivotal readouts for the reformulated tarcocimab could demonstrate improved immediacy and treatment durability versus current therapies, strengthening regulatory and commercial prospects.
Bears Say
Cash Runway And Financing RiskLimited cash runway combined with high cash burn increases the likelihood of additional financing, which could dilute existing holders and place downward pressure on the stock.
Cataract Safety SignalHeightened cataract rates observed with the original formulation confounded visual acuity outcomes and leave lingering safety concerns that could undermine confidence in the reformulated program.
Prior Late‑stage Failures And Efficacy UncertaintyPrevious late-stage trial failures with the conjugated approach create uncertainty that the reformulation will deliver improved efficacy, keeping investor skepticism elevated.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $31.18 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $1.36B.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Mar 26, 2026 which is tomorrow.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$1.037 by -$0.123.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -1.04.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 61,048,428 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$1.16 in its last earnings report, missing expectations of -$1.037. Following the earnings report the stock price went up 3.392%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.75 (91.08% Upside)
$41.75 (91.08% Upside)
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 18.4%
Last 30 Days ▲ 18.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
433.33%
12-Months-Change
Fundamentals
Return on Equity
-246.19%
Trailing 12-Months
Asset Growth
-41.48%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KOD Stock 12 Month Forecast
Average Price Target
$41.75
▲(91.08% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---